Biomarin Pharmaceutical (BMRN) Operating Expenses (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Operating Expenses came in at $636.6 million in Q1 2026, up 22.12% YoY from $521.3 million in Q1 2025, and down 30.75% on a QoQ basis from $919.2 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Operating Expenses (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Operating Expenses data on file, last reported at $636.6 million in Q1 2026.
- Quarterly Operating Expenses rose 22.12% year-over-year to $636.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 25.59% YoY) and the FY2025 annual result came in at $2.8 billion, up 18.66% from the prior year.
- Operating Expenses declined to $636.6 million in Q1 2026, from $919.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $919.2 million in Q4 2025 to a low of $382.0 million in Q1 2022.
- A 5-year average of $587.4 million and a median of $550.8 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses declined 17.12% — and 2025, when it jumped 56.88%.
- Tracing BMRN's Operating Expenses over 5 years: stood at $550.6 million in 2022, then rose by 12.4% to $618.9 million in 2023, then slipped by 5.34% to $585.9 million in 2024, then jumped by 56.88% to $919.2 million in 2025, then sank by 30.75% to $636.6 million in 2026.
- The last three Operating Expenses figures came in at $636.6 million (Q1 2026), $919.2 million (Q4 2025), and $822.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 878.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 878.79 Mn |
| Mar 31, 2026 | 636.57 Mn |
| Dec 31, 2025 | 919.18 Mn |
| Sep 30, 2025 | 822.83 Mn |
| Jun 30, 2025 | 548.52 Mn |
| Mar 31, 2025 | 521.25 Mn |
| Dec 31, 2024 | 585.91 Mn |
| Sep 30, 2024 | 631.85 Mn |
| Jun 30, 2024 | 591.58 Mn |
| Mar 31, 2024 | 560.37 Mn |
| Dec 31, 2023 | 618.93 Mn |
| Sep 30, 2023 | 550.80 Mn |
| Jun 30, 2023 | 529.71 Mn |
| Mar 31, 2023 | 534.01 Mn |
| Dec 31, 2022 | 550.63 Mn |
| Sep 30, 2022 | 507.76 Mn |
| Jun 30, 2022 | 494.65 Mn |
| Mar 31, 2022 | 382.03 Mn |
| Dec 31, 2021 | 515.69 Mn |
| Sep 30, 2021 | 461.96 Mn |